Treatment for hyperkalemia varies according to severity. In acute hyperkalemia, which often results from a particular event, such as trauma, doctors may use dialysis and intravenous medications to ...

ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd.

A new risk model may help identify which patients with chronic kidney disease (CKD) and diabetes are more likely to develop hyperkalemia, granting physicians more confidence in prescribing medications ...

Please provide your email address to receive an email when new articles are posted on . Hyperkalemia associated with renin-angiotensin-aldosterone system inhibitors therapy can be effectively managed.

A real-world study finds reduced RAASi-related hyperkalemia risk among at-risk patients initiating SGLT2 inhibitors. Sodium glucose cotransporter 2 inhibitor (SGLT2i) use is associated with lower ...

SGLT2i and GLP-1RA are associated with lower risks of hyperkalemia compared with DPP4i in patients with CKD and type 2 diabetes. Hyperkalemia risks in patients with chronic kidney disease (CKD) and ...